Vesicular Nucleotide Transport: A Brief History and the Vesicular Nucleotide Transporter as a Target for Drug Development

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|20|16|2745-2749

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.16, 2014-05, pp. : 2745-2749

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The vesicular monoamine transporter is not regulated by dopaminergic drug treatments

By Borght T.V.   Kilbourn M.   Desmond T.   Kuhl D.   Frey K.  

European Journal of Pharmacology, Vol. 294, Iss. 2, 1995-12 ,pp. : 577-583

Elsevier

Access to resources Recommend Favorite

Development of Vesicular Acetylcholine Transporter Ligands: Molecular Probes for Alzheimers Disease

By  

Current Bioactive Compounds, Vol. 6, Iss. 3, 2010-09 ,pp. : 129-155

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitors of the Glutamate Vesicular Transporter (VGLUT)

By  

Current Medicinal Chemistry, Vol. 12, Iss. 18, 2005-08 ,pp. : 2041-2056

Bentham Science Publishers

Access to resources Recommend Favorite

Impact of psychostimulants on vesicular monoamine transporter function

By Fleckenstein A.E.   Hanson G.R.  

European Journal of Pharmacology, Vol. 479, Iss. 1, 2003-10 ,pp. : 283-289

Elsevier

Access to resources Recommend Favorite

Binding of -dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific

By Kilbourn M.   Lee L.   Borght T.V.   Jewett D.   Frey K.  

European Journal of Pharmacology, Vol. 278, Iss. 3, 1995-05 ,pp. : 249-252

Elsevier

Access to resources Recommend Favorite